Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Conditions:   Cancer;   Solid Tumor;   Solid Carcinoma;   Advanced Cancer;   DIPG Brain Tumor;   Ovary Cancer;   Breast Cancer;   Papillary Thyroid Cancer;   Head and Neck Cancer;   Gastric Cancer;   Nsclc;   Mesotheliomas Pleural;   Mesothelioma Peritoneum;   Esophageal Cancer;   Diffuse Midline Glioma, H3 K27M-Mutant;   Endometrial Cancer;   Cervical Cancer;   Melanoma;   Colorectal Cancer
Interventions:   Drug: AMXT1501;   Drug: DFMO
Sponsor:   Aminex Therapeutics, Inc.

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 16, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine